U.S. Legislation Passed to Promote Research and Awareness of Scleroderma PDF Print E-mail
Saturday, 02 October 2010 00:50
The Scleroderma Foundation (U.S.) has applauded the U.S. House of Representatives for the passage of the Scleroderma Research and Awareness Act (H.R. 2408), introduced last March by Rep. Lois Capps (D-CA) and Rep. Vern Ehlers (R-MI). This bipartisan legislation gives hope to the estimated 300,000 Americans and their families living with this devastating disease.

The "Scleroderma Research and Awareness Act" will:
Direct the National Institutes of Health to intensify and coordinate activities relating to scleroderma, including:
  • Research on etiology and the development of new treatments.
  • Evaluate new treatments through clinical trials.
  • Research on the relationship between scleroderma and secondary conditions including: pulmonary hypertension, gastroparesis, Raynaud's phenomenon and Sjorgen's syndrome
  • Support for the training of new investigators
Direct the Centers for Disease Control and Prevention to establish a scleroderma public awareness campaign highlighting disease symptoms, prevalence, related conditions, and the importance of early diagnosis.

"The Scleroderma Foundation is proud to be in the forefront of advocating for greater research for this devastating disease," commented Joseph P. Camerino, Ph.D., Chair of the Foundation's National Board of Directors. "With the passage of this landmark legislation, the scleroderma community has even greater hope that a cure will be found."

For further information, please visit the source article here.
 
More articles :

» Rituximab Shows Promise in Scleroderma

Rituximab (Rituxan) improved lung function in patients with , a small proof-of-principle study found.At one year, patients randomized to receive rituximab had a median 10.25% increase in forced vital capacity (FVC) compared with baseline, while...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers

Systemic sclerosis- (SSc-) related vasculopathy, as manifested by Raynaud’s Phenomenon (RP) and digital ulcers (DUs), is associated with significant impairment of the quality of life and morbidity. The current vasoactive approach for SSc-RP,...

» Second Systemic Sclerosis World Congress a Success

Great success for the second Systemic Sclerosis World Congress that was held in February at the Palacio de Congresos de Madrid.After the positive experience of 2010 in Florence, organised the second edition the congress, on behalf of World...

» Diagnosis, Management and Prevention of Scleroderma Renal Disease

Henry Penn; Christopher P. DentonPosted: 11/14/2008; Curr Opin Rheumatol. 2008;20(6):692-696. © 2008 Lippincott Williams & WilkinsPurpose of Review: Renal complications are important in scleroderma (systemic sclerosis) and include scleroderma...

» Potential Therapy for Scleroderma Lung Disease Uncovered

Investigators, partially supported by the , have found that a deficiency in the protein caveolin-1 (cav-1) is linked to the development of, the scarring of lung tissue that causes disability and death in people with . The scientists, from the...

» Calcium Deposits Under the Skin

Numerous health effects or conditions are associated with calcinosis or calcium deposits under the skin. According to the , calcinosis is the medical term for calcium deposits that can form under the skin or in the muscles. Calcium deposits in these...